Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. November 2015 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update

NORCROSS, Ga., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
23. Oktober 2015 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Selected to Present at Cavendish Global Health Impact Forum

NORCROSS, Ga., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today...
19. Oktober 2015 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics' GR-MD-02 to be Studied in Combination With Keytruda(R) in Patients With Metastatic Melanoma

NORCROSS, Ga., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces...
07. Oktober 2015 16:08 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference

NORCROSS, Ga., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
24. September 2015 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02

NORCROSS, Ga., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces...
22. September 2015 10:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at 2015 Ladenburg Thalmann Healthcare Conference

NORCROSS, Ga., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today...
16. September 2015 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis

NORCROSS, Ga., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces...
08. September 2015 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics to Participate in Three Investment Conferences in September

NORCROSS, Ga., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that...
13. August 2015 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases

NORCROSS, Ga., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces...
10. August 2015 08:00 ET | Quelle: Galectin Therapeutics Inc.

Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results

NORCROSS, Ga., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...

Vorherige Seite